Changes in Respiratory Function and Physical Capacity among Smokers after Switching to IQOS: One Year Follow-Up
DOI:
https://doi.org/10.12974/2312-5470.2020.06.03Keywords:
COPD, Combustible Cigarettes, “Heat-Not-Burn" Tobacco Products, IQOS, Metabolic Syndrome, Respiratory function.Abstract
Background: Combustible cigarettes (CC) smoking is a common risk factor for chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of death in Kazakhstan. Switching to "heat-not-burn" tobacco products (IQOS) has been shown to have less deleterious health effect compared to CC for those who cannot quit smoking. The goal of the study was to explore respiratory and physical effects of switching from CC to IQOS in a population of long-time smokers in Kazakhstan. Methods: Two cohorts of men and women aged between 40 and 59 residing in Almaty (a large two-million city of Kazakhstan) were recruited into two cohort of 801 CC smokers and 400 IQOS users and matched by gender, age, education, and smoking history. Analyses also included 627 CC smokers and 308 IQOS users who maintained their tobacco product use during the first year of observation. Spirometry measurements and the 6-minute walk test (6MWT) were performed as a part of the baseline and one-year comprehensive assessments. In addition to spirometry, clinical assessments included components of metabolic syndrome and anthropometry. For comparative analysis between two cohorts Student’s t-test and Chi-squared tests were used. Results: We observed significantly better outcomes for IQOS users in most of CAT scores, spirometry outcomes, and in some metabolic syndrome components. Although changes in the results between the baseline and the one-year assessments show comparable results, smokers of CC often show significantly faster decline in the health status compared to IQOS. Specifically, the changes in CAT score and in spirometry FEV1 over FVC ratios were worsening at higher pace for CC smokers compared to IQOS users. Conclusions: After one year of observation IQOS users demonstrated better outcomes for most of CAT scores and in the ratio of FEV1 over FVC in comparison to CC smokers.
References
GBD 2015 Mortality and Causes of Death Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 08;388(10053):1459–1544.
Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan KY, Sheikh A, Rudan I, Global Health Epidemiology Reference Group (GHERG) Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015 Dec;5(2):020415. https://doi.org/10.7189/jogh.05.020415
Vogelmeier C, Criner G, Martinez F, Anzueto A, Barnes P, Bourbeau J, Celli B, Chen R, Decramer M, Fabbri L, Frith Peter, Halpin DMG, López VMV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Dec 01;195(5):557–582. https://doi.org/10.1164/rccm.201701-0218pp
Shah T, Churpek MM, Coca PM, Konetzka RT. Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the read missions penalty expansion. Chest. 2015 May;147(5):1219–1226. doi: 10.1378/chest.14-2181. http://europepmc.org/abstract/MED/25539483. https://doi.org/10.1378/chest.14-2181
GBD 2015 Chronic Respiratory Disease Collaborators Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691–706. doi: 10.1016/S2213-2600(17)30293-X. https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(17)30293-X.
MacNee W. Pathology, pathogenesis, and pathophysiology. BMJ. 2006 May 18;332(7551):1202–1204. doi: 10.1136/bmj.332.7551.1202. https://doi.org/10.1136/bmj.332.7551.1202
Global Initiative for Chronic Obstructive Lung Disease. 2017. Global Strategy for the Diagnosis, Management and Prevention of COPD https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann Holger, Wedzicha W, MacDonald R, Shekelle P, American College of Physicians. American College of Chest Physicians. American Thoracic Society. European Respiratory Society Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 02;155(3):179–191. https://doi.org/10.7326/0003-4819-155-3-201108020-00008
Cebron LN, Beijers RJHCG, van der Bost B, Doehner W, Lainscak M, Schols AMWJ. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD. 2016 Dec;13(3):399–406. doi: 10.3109/15412555.2016.1140732. https://doi.org/10.3109/15412555.2016.1140732
Sharman A, Zhussupov B, Sharman D, Stambekova A, Yeraliyev S. Cross-Sectional Study of Chronic Obstructive Pulmonary Disease Prevalence Among Smokers, Ex-Smokers, and Never-Smokers in Almaty, Kazakhstan: Study Protocol. JMIR Res Protoc. 2017 Jul 25;6(7):e143. http://www.researchprotocols.org/2017/7/e143/. https://doi.org/10.2196/resprot.7422
Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Lazarus SC, Martinez FJ, Paine R, Rennard S, Tashkin DP, Han MK, SPIROMICS Research Group Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med. 2016 May 12;374(19):1811–1821. http://europepmc.org/abstract/MED/27168432. https://doi.org/10.1056/nejmoa1505971
Regan EA, Lynch DA, Curran-Everett D, Curtis JL, Austin JHM, Grenier PA, Kauczor H, Bailey WC, DeMeo DL, Casaburi RH, Friedman P, Van Beek EJR, Hokanson JE, Bowler RP, Beaty TH, Washko GR, Han MK, Kim V, Kim SS, Yagihashi K, Washington L, McEvoy CE, Tanner C, Mannino DM, Make BJ, Silverman EK, Crapo JD, Genetic Epidemiology of COPD (COPDGene) Investigators Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med. 2015 Sep;175(9):1539–1549. http://europepmc.org/abstract/MED/26098755. https://doi.org/10.1001/jamainternmed.2015.2735
Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977 Jun 25;1(6077):1645–1648. http://europepmc.org/abstract/MED/871704. https://doi.org/10.1136/bmj.1.6077.1645
Haziza C, de la Bourdonnaye G, Merlet S, Benzimra M, Ancerewicz J, Donelli A, Baker G, Picavet P, Lüdicke Frank. Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement. Regul Toxicol Pharmacol. 2016 Nov;81:489–499. https://linkinghub.elsevier.com/retrieve/pii/S0273-2300(16)30262-8. https://doi.org/10.1016/j.yrtph.2016.09.014
Polosa R, Morjaria JB, Caponnetto P, Prosperini U, Russo C, Pennisi A, Bruno CM. Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. Respir Res. 2016 Dec 16;17(1):166. https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-016-0481-x. https://doi.org/10.1186/s12931-016-0481-x
Sharman A., Zhussupov B, Sharman D, Kim Yerenchina E Lung Function in Users of a Smoke-Free Electronic Device With HeatSticks (IQOS) Versus Smokers of Conventional Cigarettes: Protocol for a Longitudinal Cohort Observational Study. JMIR Res Protoc. 2018 Nov 5;7(11):e10006. https://doi.org/10.2196/10006
Global Initiative for Chronic Obstructive Lung Disease Global Initiative for Chronic Obstructive Lung Disease. 2020 Pocket guide to COPD diagnosis, management, and prevention https://goldcopd.org/wp-content/uploads/2020/03/GOLD-2020-POCKET-GUIDE-ver1.0_FINAL-WMV.pdf
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 01;166(1):111–117. https://doi.org/10.1164/ajrccm.166.1.at1102
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948–968. doi: 10.1183/09031936.05.00035205. http://erj.ersjournals.com/cgi/pmidlookup?view=long&pmid=16264058
